SK Biopharmaceuticals Co., Ltd.
KRX:326030.KS
110800 (KRW) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 354,891.556 | 246,179.12 | 418,644.529 | 25,999.027 | 123,852.416 | 1,098.738 | 85,316.07 | 89,927.545 | 71,416.702 | 72,440.821 | 60,454.791 | 51,798.063 | 37,631.486 |
| Cost of Revenue
| 46,517.094 | 37,768.134 | 22,335.994 | 1,974.01 | 514.197 | 3,342.299 | 81,744.543 | 78,853.36 | 45,692.07 | 46,580.36 | 44,396.377 | 37,670.623 | 27,398.834 |
| Gross Profit
| 308,374.461 | 208,410.986 | 396,308.535 | 24,025.016 | 123,338.219 | -2,243.561 | 3,571.527 | 11,074.185 | 25,724.631 | 25,860.461 | 16,058.414 | 14,127.44 | 10,232.652 |
| Gross Profit Ratio
| 0.869 | 0.847 | 0.947 | 0.924 | 0.996 | -2.042 | 0.042 | 0.123 | 0.36 | 0.357 | 0.266 | 0.273 | 0.272 |
| Reseach & Development Expenses
| 137,698.137 | 122,816.743 | 114,526.335 | 108,441.385 | 176,212.762 | 121,288.489 | 85,597.819 | 53,544.925 | 56,617.44 | 54,388.246 | 49,794.525 | 35,066.063 | 22,929.322 |
| General & Administrative Expenses
| 61,726.562 | 62,435.424 | 49,961.658 | 53,734.996 | 9,067.802 | 8,944.078 | 3,889.448 | 3,078.624 | 3,721.554 | 1,964.108 | 2,163.266 | 2,758.537 | 2,669.299 |
| Selling & Marketing Expenses
| 40,141.872 | 49,886.087 | 39,839.602 | 25,360.834 | 488.735 | 227.028 | 875.932 | 1,246.461 | 1,291.799 | 866.324 | 1,070.837 | 1,057.721 | 753.521 |
| SG&A
| 204,312.85 | 112,321.511 | 89,801.26 | 79,095.83 | 9,556.537 | 9,171.106 | 4,765.38 | 4,325.085 | 5,013.353 | 2,830.432 | 3,234.103 | 3,816.258 | 3,422.82 |
| Other Expenses
| 0 | 104,350.761 | 97,022.739 | 75,986.625 | 16,827.657 | 380.485 | -157.553 | -277.763 | 82.992 | -249.022 | -1,161.201 | 899.511 | 4,321.476 |
| Operating Expenses
| 358,331.255 | 339,489.015 | 301,350.334 | 263,523.84 | 202,596.956 | 140,202.046 | 101,544.935 | 68,747.707 | 65,167.514 | 65,098.874 | 60,216.362 | 50,117.677 | 30,673.618 |
| Operating Income
| -37,522.197 | -131,078.029 | 74,247.722 | -239,498.824 | -79,258.737 | -139,103.308 | -97,973.408 | -57,673.521 | -39,442.882 | -39,238.413 | -44,157.947 | -35,990.237 | -24,307.863 |
| Operating Income Ratio
| -0.106 | -0.532 | 0.177 | -9.212 | -0.64 | -126.603 | -1.148 | -0.641 | -0.552 | -0.542 | -0.73 | -0.695 | -0.646 |
| Total Other Income Expenses Net
| -6,335.565 | -11,390.837 | -23,681.652 | -410.506 | -5,192.332 | 1,464.538 | -932.192 | 27,312.678 | 13,558.919 | 3,000.098 | 1,604.591 | 6,033.543 | 3,617.6 |
| Income Before Tax
| -43,857.762 | -142,468.864 | 71,276.548 | -239,909.329 | -84,451.069 | -137,638.771 | -96,809.478 | -30,360.843 | -25,787.562 | -36,238.315 | -42,553.356 | -29,956.694 | -20,690.263 |
| Income Before Tax Ratio
| -0.124 | -0.579 | 0.17 | -9.228 | -0.682 | -125.27 | -1.135 | -0.338 | -0.361 | -0.5 | -0.704 | -0.578 | -0.55 |
| Income Tax Expense
| -8,478.274 | -3,037.986 | 6,430.908 | 7,504.284 | -12,931.602 | 583.199 | 839.581 | 28,348.736 | 2,273.625 | 810.561 | -1,551.442 | 373.904 | -1,225.126 |
| Net Income
| -32,882.849 | -139,430.878 | 64,845.64 | -247,413.614 | -71,519.467 | -138,096.479 | -97,649.06 | -30,360.843 | -28,061.186 | -37,048.875 | -41,001.914 | -30,330.598 | -19,465.137 |
| Net Income Ratio
| -0.093 | -0.566 | 0.155 | -9.516 | -0.577 | -125.686 | -1.145 | -0.338 | -0.393 | -0.511 | -0.678 | -0.586 | -0.517 |
| EPS
| -419.89 | -1,780.43 | 828.03 | -3,447.52 | -3,652.99 | -2,219 | -1,953 | -607 | -561.25 | -749 | -1,025 | -758 | -487 |
| EPS Diluted
| -419.89 | -1,780.43 | 828.03 | -3,447.52 | -3,652.99 | -2,219 | -1,953 | -607 | -561.25 | -749 | -1,025 | -758 | -487 |
| EBITDA
| -22,204.753 | -125,768.6 | 106,600.028 | -224,588.687 | -73,981.942 | -134,264.824 | -95,767.516 | -54,588.438 | -31,563.02 | -31,897.569 | -38,908.582 | -24,195.795 | -15,298.552 |
| EBITDA Ratio
| -0.063 | -0.459 | 0.205 | -8.713 | -0.597 | -121.814 | -1.097 | -0.292 | -0.442 | -0.43 | -0.619 | -0.435 | -0.294 |